Stress urinary incontinence is a condition characterised by urine leakage when the bladder is under pressure such as when exercising or sneezing. Image credit: Shutterstock/CHAjAMP.

UroMems has reported more positive results from a trial evaluating its UroActive device for the treatment of stress urinary incontinence.

The France-headquartered company stated the first female patient implanted with the device met the six-month primary endpoint. The patient is part of UroMems female first-in-human feasibility trial (NCT05828979), which will enroll six patients in total.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The news follows the results from a male first-in-human trial (NCT05547672), which also met its six-month primary endpoints.

Both trials are running in parallel to evaluate the device in men and women with the condition who have not responded to other forms of treatment. Treatment currently involves either surgery or Eli Lily’s antidepressant Cymbalta (duloxetine).

Primary endpoints in both trials include the rate of explants and revisions six months after device activation and the rate of device activation successes.

Results from the prospective, multicentre clinical studies will support the design and planning of an upcoming pivotal trial in Europe and the US. UroMems’ CEO and co-founder Hamid Lamraoui did not disclose details of the pivotal trial to Medical Device Network.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

UroMems is carving out a new approach to manage stress urinary incontinence, a condition characterised by urine leakage when the bladder is under pressure such as when exercising or sneezing. It affects around 40 million Americans and is more common in women.

UroMem’s UroActive system uses the company’s MyoElectroMechanical System which is placed around the urethral duct and automatically changes the sphincter opening by pressure adjustments based on the patient’s activity. This has the advantage of not placing sustained pressure on the tissue when the patient is at rest.

In April 2023, the US Food and Drug Administration (FDA) granted UroActive with Safer Technologies Programme designation to speed up the device’s route to market.

In November 2023, Aviation Medical released positive data on its non-invasive bladder-control device for the treatment of urinary urgency and urge urinary incontinence caused by overactive bladder syndrome.

The pharma industry is also joining the medtech world in targeting new treatment options for patients with stress urinary incontinence. In November 2023, Switzerland-based Versameb received approval from the FDA to begin a Phase I clinical trial with the company’s mRNA therapy in women with the condition.